Comment: Laparoscopic versus open resection for colorectal liver metastases
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
Comment: Laparoscopic versus open resection for colorectal liver metastases ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )
13 Jun 2019
CheckMate-142: Updated data from MSI high metastatic colon cancer patients
Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA
CheckMate-142: Updated data from MSI high metastatic colon cancer patients ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )
13 Jun 2019
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0...
Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany
VOLFI trial final results: mFOLFOXIRI and panitumumab versus FOLFOXIRI in ECOG 0-1 and primarily non-resectable mCRC patients ( Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany )
10 Jun 2019
Highlights from ASCO 2019
Asst. Prof Bishal Gyawali and Monique Biryiana
Highlights from ASCO 2019 ( Asst. Prof Bishal Gyawali and Monique Biryiana )
3 Jun 2019
Long-term survival after laparoscopic versus open resection for colorectal liver...
Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway
Long-term survival after laparoscopic versus open resection for colorectal liver metastases ( Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway )
3 Jun 2019
No difference in survival between laparoscopic surgery and open surgery in color...
Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway
No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases ( Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway )
3 Jun 2019
Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer wi...
Prof Arnaud Mejean - Paris Descartes University, Paris, France
Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population ( Prof Arnaud Mejean - Paris Descartes University, Paris, France )
3 Jun 2019
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitin...
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )
1 Jun 2019
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junc...
Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spa...
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain )
1 Jun 2019
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemothera...
Dr Richard Schilsky and Dr Josep Tabernero
Comment: Reasonable to conclude that pembrolizumab is non-inferior to chemotherapy ( Dr Richard Schilsky and Dr Josep Tabernero )
1 Jun 2019
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or g...
Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Sp...
Pembrolizumab comparable to chemotherapy for patients with advanced gastric or gastroesophageal junction cancers ( Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital , Barcelona, Spain )
1 Jun 2019
IMPACT: Improving Management of Advanced Colorectal Tumours
Mr Steve Clark, Patient Advocate for Bowel Cancer UK and Expert Patient for ACPG...
IMPACT: Improving Management of Advanced Colorectal Tumours ( Mr Steve Clark, Patient Advocate for Bowel Cancer UK and Expert Patient for ACPGBI )
21 May 2019